Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Portable Biosensor Diagnoses Psychiatric Disorders Using Saliva Samples

By LabMedica International staff writers
Posted on 10 Nov 2025

Early diagnosis of psychiatric disorders such as depression, schizophrenia, and bipolar disorder remains one of medicine’s most pressing challenges. More...

Current diagnostic methods rely heavily on clinical evaluations and symptoms that appear long after underlying biological changes occur. Now, researchers have developed a low-cost, portable biosensor capable of detecting a protein whose altered levels are associated with several mental health disorders—paving the way for faster and more accessible screening.

The new biosensor, developed by researchers from the University of São Paulo (São Carlos, Brazil; www5.usp.br) in collaboration with Embrapa Instrumentação (São Carlos, Brazil), consists of a flexible strip with electrodes that can analyze saliva samples when connected to a portable reader. In less than three minutes, it measures the concentration of brain-derived neurotrophic factor (BDNF)—a protein critical for neuron growth, maintenance, and cognitive functions such as learning and memory.

Clinically, BDNF is a biomarker of psychiatric and neurological health. Low BDNF levels have been linked to depression, cognitive decline, and other mental health disorders, while effective antidepressant treatment tends to restore them. Healthy individuals typically have BDNF concentrations above 20 nanograms per milliliter (ng/mL), whereas those with major depressive disorder often fall below 10–12 ng/mL.

The new biosensor, described in ACS Polymers Au, can detect extremely low protein concentrations—from 10⁻²⁰ to 10⁻¹⁰ grams per milliliter—with an estimated cost of just USD 2.19 per unit. The team engineered a screen-printed flexible strip composed of three electrodes: one functionalized working electrode modified with carbon nanospheres, one pure carbon auxiliary electrode, and one silver reference electrode.

Additional chemical layers—polyethyleneimine, glutaraldehyde, and ethanolamine—were used to increase sensitivity, stabilize the antibody binding, and prevent non-specific reactions. BDNF detection is based on the formation of antibody-antigen immunocomplexes, which change the electrical resistance on the sensor’s surface. This is measured using electrochemical impedance spectroscopy, a highly sensitive technique for monitoring molecular interactions.

The results are wirelessly transmitted via Bluetooth to a mobile device, allowing clinicians or users to visualize the data in real time. Unlike conventional tests such as ELISA, fluorescence assays, or high-performance liquid chromatography, which require specialized laboratories and long processing times, the biosensor offers speed, simplicity, and portability—ideal for point-of-care and field use.

"There are few sensors that perform this type of analysis, and ours was the one that performed best. It detected a wide range of concentrations, which is a very good result from a clinical point of view. When protein levels are very low, it can serve as a warning sign for diseases and psychiatric disorders," said Paulo Augusto Raymundo Pereira, corresponding author of the article. “On the other hand, by being able to signal an increase in BDNF, it contributes as a tool to monitor the patient's progress according to the treatment.”

Related Links:
University of São Paulo
Embrapa Instrumentação


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
HPV Test
Allplex HPV28 Detection
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The test combines RNA signals from the tumor-immune microenvironment to predict treatment response, rather than relying on a single marker such as PD-L1 expression.(Image Credit: Adobe Stock)

RNA-Based Test Predicts Immunotherapy Response in Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) represents the largest U.S. patient population eligible for immune checkpoint inhibitor therapy. Treatment selection often relies on PD-L1 expression, but a single protein... Read more

Immunology

view channel
Image Credit: Adobe Stock

Immune Profiling Identifies Early Maternal Autoantibodies Linked to Preterm Birth Risk

A typical pregnancy lasts about 40 weeks, but labor begins prematurely in roughly one in 10 pregnancies. Preterm birth is the leading cause of newborn death worldwide, yet its underlying causes and which... Read more

Industry

view channel
Image Credit: iStock

Global TB Summit Connects Diagnostic Testing With Prevention and Clinical Care

Tuberculosis remains a major global infectious disease challenge despite declining deaths. In 2024, an estimated 10.7 million people worldwide developed the disease and nearly 1.2 million died from it.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.